2Boucher BJ (1998) Inadequate vitamin D status: does it contribute to the disorders comprising syndrome ‘X’? Br J Nutr 79, 315–327.
3Teegarden D (2006) . In Calcium and Human Health, pp. 401–409 [Weaver C and Heaney R, editors]. Totowa, NJ: Humana Press Inc.
4Mathieu C, Gysemans C, Giulietti A, et al. . (2005) Vitamin D and diabetes. Diabetologia 48, 1247–1257.
5Mathieu C, Van Etten E, Decallonne B, et al. . (2004) Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol 89–90, 449–452.
6Hebert SC, Brown EM & Harris HW (2004) Role of the Ca2+-sensing receptor in divalent mineral ion homeostasis. J Exp Biol 200, 295–302.
7Zierold C, Mings JA & Deluca HF (2003) Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. J Cell Biochem 88, 234–237.
8Heaney RP (2003) Sensitivity of parathyroid hormone response to calcium intake. Am J Clin Nutr 78, 493–495.
9Harkness L & Cromer B (2005) Low levels of 25-hydroxy vitamin D are associated with elevated parathyroid hormone in healthy adolescent females. Osteoporosis Int 16, 109–113.
10Krall EA, Sahyoun N, Tannenbaum S, et al. . (1989) Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N Engl J Med 321, 1777–1783.
11Weaver CM & Fleet JC (2004) Vitamin D requirements: current and future. Am J Clin Nutr 80, 1735S–1739S.
12Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. . (2002) Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 76, 187–192.
13Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80, 1678S–1688S.
14Heaney RP & Weaver CM (2003) Calcium and vitamin D. Endocrinol Metab Clin North Am 32, 181–194, .
15Procopio M & Borretta G (2003) Derangement of glucose metabolism in hyperparathyroidism. J Endocrinol Invest 26, 1136–1142.
16Pittas AG, Lau J, Hu FB, et al. . (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92, 2017–2029.
17Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, et al. . (2008) Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 10, 185–197.
18Choi HK, Willett WC, Stampfer MJ, et al. . (2005) Dairy consumption and risk of type 2 diabetes mellitus in men – a prospective study. Arch Intern Med 165, 997–1003.
19Parikh SJ & Yanovski JA (2003) Calcium intake and adiposity. Am J Clin Nutr 77, 281–287.
20Teegarden D (2005) The influence of dairy product consumption on body composition. J Nutr 135, 2749–2752.
21Lin YC, Lyle RM, McCabe LD, et al. . (2000) Dairy calcium is related to changes in body composition during a two-year exercise intervention in young women. J Am Coll Nutr 19, 754–760.
22Zemel MB, Shi H, Greer B, et al. . (2000) Regulation of adiposity by dietary calcium. FASEB J 14, 1132–1138.
23Barr SI (2003) Increased dairy product or calcium intake: is body weight or composition affected in humans? J Nutr 133, 245S–248S.
24Shapses SA, Heshka S & Heymsfield SB (2004) Effect of calcium supplementation on weight and fat loss in women. J Clin Endocrinol Metab 89, 632–637.
25Gunther CW, Legowski PA, Lyle RM, et al. . (2005) Dairy products do not lead to alterations in body weight or fat mass in young women in a 1-y intervention. Am J Clin Nutr 81, 751–756.
26Teegarden D, White KM, Lyle RM, et al. . (2008) Calcium and dairy product modulation of lipid utilization and energy expenditure. Obesity (Silver Spring) 16, 1566–1572.
27McGill AT, Stewart JM, Lithander FE, et al. . (2008) Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 7, 4.
28Pfeifer M, Begerow B & Minne HW (2002) Vitamin D and muscle function. Osteoporos Int 13, 187–194.
29Boland R (1986) Role of vitamin D in skeletal muscle function. Endocr Rev 7, 434–448.
30Visser M, Deeg DJ & Lips P (2003) Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 88, 5766–5772.
31Bischoff HA, Stahelin HB, Urscheler N, et al. . (1999) Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 80, 54–58.
32Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. . (2004) Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged>or = 60 y. Am J Clin Nutr 80, 752–758.
33Pfeifer M, Begerow B, Minne HW, et al. . (2001) Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 109, 87–92.
34Mowe M, Haug E & Bohmer T (1999) Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc 47, 220–226.
35Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. . (2004) Effect of vitamin D on falls: a meta-analysis. JAMA 291, 1999–2006.
36Arabi A, Baddoura R, Awada H, et al. . (2006) Hypovitaminosis D osteopathy: is it mediated through PTH, lean mass, or is it a direct effect? Bone 39, 268–275.
37Sato Y, Iwamoto J, Kanoko T, et al. . (2005) Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis 20, 187–192.
38Siddiqui S, Chang E, Zou M, et al. . (2007) High dietary calcium and vitamin D effects on fat mass accretion and expression of liver enzymes in rats. FASEB J 21, A56.
39Endo I, Inoue D, Mitsui T, et al. . (2003) Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144, 5138–5144.
40Liu S, Song Y, Ford ES, et al. . (2005) Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 28, 2926–2932.
41Pittas AG, Dawson-Hughes B, Li T, et al. . (2006) Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29, 650–656.
42Scragg R, Sowers M & Bell C (2004) Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27, 2813–2818.
43Martins D, Wolf M, Pan D, et al. . (2007) Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167, 1159–1165.
44Reis JP, von Mühlen D, Kritz-Silverstein D, et al. . (2007) Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 30, 1549–1555.
45Ford ES, Ajani UA, McGuire LC, et al. . (2005) Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care 28, 1228–1230.
46Baynes KCR, Boucher BJ, Feskens EJM, et al. . (1997) Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 40, 344–347.
47Need AG, O'Loughlin PD, Horowitz M, et al. . (2005) Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol 62, 738–741.
48Targher G, Bertolini L, Padovani R, et al. . (2006) Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol 65, 593–597.
49Scragg R, Holdaway I, Singh V, et al. . (1995) Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 27, 181–188.
50Chiu KC, Chu A, Go VL, et al. . (2004) Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 79, 820–825.
51Boucher BJ, Mannan N, Noonan K, et al. . (1995) Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 38, 1239–1245.
52McCarty MF & Thomas CA (2003) PTH excess may promote weight gain by impeding catecholamine-induced lipolysis – implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses 61, 535–542.
53Bolland MJ, Grey AB, Gamble GD, et al. . (2005) Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrin Metab 90, 1525–1530.
54Bell NH, Epstein S, Greene A, et al. . (1985) Evidence for alteration of the vitamin D–endocrine system in obese subjects. J Clin Invest 76, 370–373.
55Atkinson RL, Dahms WT, Bray GA, et al. . (1978) Parathyroid hormone levels in obesity: effects of intestinal bypass surgery. Miner Electrolyte Metab 1, 315–320.
56Pittas AG, Harris SS, Stark PC, et al. . (2007) The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 30, 980–986.
57de Boer IH, Tinker LF, Connelly S, et al. . (2008) Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 31, 701–707.
58Borissova AM, Tankova T, Kirilov G, et al. . (2003) The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 57, 258–261.
59Allegra V, Luisetto G, Mengozzi G, et al. . (1994) Glucose-induced insulin secretion in uremia: role of 1α,25(HO)2-vitamin D3. Nephron 68, 41–47.
60Mak RH (1998) 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53, 1353–1357.
61Orwoll E, Riddle M & Prince M (1994) Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 59, 1083–1087.
62Raghuramulu N, Raghunath M, Chandra S, et al. . (1992) Vitamin D improves oral glucose tolerance and insulin secretion in human diabetes. J Clin Biochem Nutr 13, 45–51.
63Ayesha I, Raghunath M, Sesikeran B, et al. . (1998) Effect of oral administration of vitamin D on glucose tolerance and insulin secretion in type 2 diabetes mellitus. Diabetes Nutr Metab 11, 261–265.
64Szathmary EJ (1987) The effect of Gc genotype on fasting insulin level in Dogrib Indians. Hum Genet 75, 368–372.
65Iyengar S, Hamman RF, Marshall JA, et al. . (1989) On the role of vitamin D binding globulin in glucose homeostasis: results from the San Luis Valley Diabetes Study. Genet Epidemiol 6, 691–698.
66Baier LJ, Dobberfuhl AM, Pratley RE, et al. . (1998) Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 83, 2993–2996.
67Hirai M, Suzuki S, Hinokio Y, et al. . (1998) Group specific component protein genotype is associated with NIDDM in Japan. Diabetologia 41, 742–743.
68Hirai M, Suzuki S, Hinokio Y, Hirai A, et al. . (2000) Variations in vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance. J Clin Endocrinol Metab 85, 1951–1953.
69Ye WZ, Dubois-Laforgue D, Bellanne-Chantelot C, et al. . (2001) Variations in the vitamin D-binding protein (Gc locus) and risk of type 2 diabetes mellitus in French Caucasians. Metabolism 50, 366–369.
70Klupa T, Malecki M, Hanna L, et al. . (1999) Amino acid variants of the vitamin D-binding protein and risk of diabetes in white Americans of European origin. Eur J Endocrinol 141, 490–493.
71Oh JY & Barrett-Connor E (2002) Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study. Metabolism 51, 356–359.
72Malecki MT, Frey J, Moczulski D, et al. . (2003) Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population. Exp Clin Endocrinol Diabetes 111, 505–509.
73Ortlepp JR, Metrikat J, Albrecht M, et al. . (2003) The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med 20, 451–454.
74Ye WZ, Reis AF, Dubois-Laforgue D, et al. . (2001) Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. Eur J Endocrinol 145, 181–186.
75Malecki MT, Klupa T, Wolkow P, et al. . (2003) Association study of the vitamin D: 1α-hydroxylase (CYP1α) gene and type 2 diabetes mellitus in a Polish population. Diabetes Metab 29, 119–124.
76Smogorzewski M, Zayed M, Zhang YB, et al. . (1993) Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol 264, H1998–H2006.
77Ni Z, Smogorzewski M & Massry SG (1994) Effects of parathyroid hormone on cytosolic calcium of rat adipocytes. Endocrinology 135, 1837–1844.
78Christakos S, Dhawan P, Liu Y, et al. . (2003) New insights into the mechanisms of vitamin D action. J Cell Biochem 88, 695–705.
79Zehnder D, Bland R, Williams MC, et al. . (2001) Extrarenal expression of 25-hydroxyvitamin D(3)-1α-hydroxylase. J Clin Endocrinol Metab 86, 888–894.
80Flanagan JN, Wang L, Tangpricha V, et al. . (2003) Regulation of the 25-hydroxyvitamin D-1α-hydroxylase gene and its splice variant. Recent results. Cancer Res 164, 157–167.
81Li J, Byrne ME, Chang E, et al. . (2008) 1α-25-Dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem 112, 122–126.
82Ishida H, Suzuki K, Someya Y, et al. . (1993) Possible compensatory role of parathyroid hormone-related peptide on maintenance of calcium homeostasis in patients with non-insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 129, 519–524.
83Kadowaki S & Norman AW (1984) Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 73, 759–766.
84Bourlon PM, Faure-Dussert A, Billaudel B, et al. . (1996) Relationship between calbindin-D28K levels in the A and B cells of the rat endocrine pancreas and the secretion of insulin and glucagon: influence of vitamin D3 deficiency and 1,25-dihydroxyvitamin D3. J Endocrinol 148, 223–232.
85Bourlon PM, Billaudel B & Faure-Dussert A (1999) Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 160, 87–95.
86Billaudel BJ, Bourlon PM, Sutter BC, et al. . (1995) Regulatory effect of 1,25-dihydroxyvitamin D3 on insulin release and calcium handling via the phospholipid pathway in islets from vitamin D-deficient rats. J Endocrinol Invest 18, 673–682.
87Bourlon PM, Faure-Dussert A & Billaudel B (1997) Modulatory role of 1,25 dihydroxyvitamin D3 on pancreatic islet insulin release via the cyclic AMP pathway in the rat. Br J Pharmacol 121, 751–758.
88Bland R, Markovic D, Hills CE, et al. . (2004) Expression of 25-hydroxyvitamin D3-1α-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 89–90, 121–125.
89Huang Y, Ishizuka T, Miura A, et al. . (2002) Effect of 1α,25-dihydroxy vitamin D3 and vitamin E on insulin-induced glucose uptake in rat adipocytes. Diabetes Res Clin Pract 55, 175–183.
90Maestro B, Davila N, Carranza MC, et al. . (2003) Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 84, 223–230.
91Maestro B, Campion J, Davila N, et al. . (2000) Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 47, 383–391.
92Pepe J, Romagnoli E, Nofroni I, et al. . (2005) Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int 16, 805–812.
93Teegarden D, Legowski P, Gunther CW, et al. . (2005) Dietary calcium intake protects women consuming oral contraceptives from spine and hip bone loss. J Clin Endocrinol Metab 90, 5127–5133.
94Kumar S, Olukoga AO, Gordon C, et al. . (1994) Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 40, 47–53.
95Malecki MT, Klupa T, Wanic K, et al. . (2002) Vitamin D binding protein gene and genetic susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 57, 99–104.
96Taylor WH & Khaleeli AA (2001) Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 17, 175–180.
97Chiu KC, Chuang LM, Lee NP, et al. . (2000) Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 49, 1501–1505.
98Thomas DM, Rogers SD, Sleeman MW, et al. . (1995) Modulation of glucose transport by parathyroid hormone and insulin in UMR 106-01, a clonal rat osteogenic sarcoma cell line. J Mol Endocrinol 14, 263–275.
99Reusch JE, Begum N, Sussman KE, et al. . (1991) Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 129, 3269–3273.
100Perna AF, Fadda GZ, Zhou XJ, et al. . (1990) Mechanisms of impaired insulin secretion after chronic excess of parathyroid hormone. Am J Physiol 259, F210–F216.
101Chang E, Donkin S & Teegarden D (2007) Parathyroid hormone modulates insulin-stimulated glucose uptake in differentiated adipocytes. FASEB J 21, A1111.
102Zhang Z, Yuan W, Sun L, et al. . (2007) 1,25-Dihydroxyvitamin D3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 72, 193–201.
103Sun J, Kong J, Duan Y, et al. . (2006) Increased NF-κB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 291, E315–E322.
104Adams LS & Teegarden D (2004) 1,25-Dihydroxycholecalciferol inhibits apoptosis in C3H10T1/2 murine fibroblast cells through activation of nuclear factor κB. J Nutr 134, 2948–2952.
105Cohen-Lahav M, Shany S, Tobvin D, et al. . (2006) Vitamin D decreases NFκB activity by increasing IκBα levels. Nephrol Dial Transplant 21, 889–897.
106Cohen-Lahav M, Douvdevani A, Chaimovitz C, et al. . (2007) The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol 103, 558–562.
107Giulietti A, van Etten E, Overbergh L, et al. . (2007) Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 77, 47–57.
108Krishnan AV, Moreno J, Nonn L, et al. . (2007) Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res 22, Suppl. 2, V74–V80.
109Miele C, Riboulet A, Maitan MA, et al. . (2003) Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C α-mediated mechanism. J Biol Chem 278, 47376–47387.
110Talmor Y, Golan E, Benchetrit S, et al. . (2008) Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 294, F1059–F1064.